Project Grant HT94252410625
Award Date
9/30/24
Completion Date
9/29/28
Dollars Obligated
$655K
Federal Agency
Defense Health Agency
Awardee
Dignity Health (SKX6AXF9ZTM3)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Phoenix, AZ 85013, USA
Similar Awards
This $649,762 federal Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) supports research by Dignity Health's St. Joseph's Hospital and Medical Center (Barrow Neurological Institute) to investigate maladaptive 5-HT raphe-corticolimbic plasticity underlying the development of non-motor symptoms in Parkinson's disease. The award period runs from September 30, 2024 through September 29, 2028. As a prime recipient,...
The Department of the Army Medical Command awarded a $722,545 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Dignity Health's St. Joseph's Hospital and Medical Center in San Francisco, CA. The grant will fund a 2-year research project to investigate the role of TDP-43 associated cryptic exon inclusion in C9ORF72-mediated cortical neurodegeneration. The project aims to advance understanding of the molecular mechanisms underlying neurological disorders...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,487,072.00 to Dignity Health's St. Joseph's Hospital and Medical Center in Phoenix, AZ to develop a novel bifunctional agent as a radiosensitizer for glioblastoma and a radioprotector of normal brain. The award has an initial term from August 15, 2024 to August 14, 2027. The key products or services to be delivered through this funding include...
The U.S. Department of Defense's Defense Health Agency awarded a $1,119,598 Project Grant to Dignity Health, doing business as St. Joseph's Hospital and Medical Center, for the research project "AD Genetic Risk as a Prognostic Factor for Cognitive Outcomes after TBI" under the Military Medical Research and Development program (CFDA 12.420). This 4-year award, effective from September 30, 2024 to September 29, 2028, will fund innovative biomedical research focused on understanding the...
This $2,000,000 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research on the interrelationship between the PINK1-PRKN pathway disruption and tauopathy in the pathophysiology of cognitive impairment in Parkinson's disease. The award, with a performance period from June 1, 2025 to May 31, 2028, was granted to the Board of Regents of the University of Nebraska, through its University of Nebraska Medical...
The Defense Health Agency awarded a $365,623 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Fundacio De Recerca Clinic Barcelona-Institut D'investigacions Biomediques August Pi I Sunyer, a non-profit biomedical research organization in Barcelona, Spain. The grant, awarded on September 1, 2024, will support the development of a novel blood-based diagnostic test to detect alpha-synuclein aggregation as an indicator of Parkinson's disease. The...
This federal Project Grant award of $673,448.00, provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research focused on transforming healthcare for military service members and the broader public. The award was granted to The Research Foundation For The State University Of New York (RF SUNY) to conduct research on the "MALADAPTIVE 5-HT RAPHE-CORTICOLIMBIC PLASTICITY UNDERLYING THE...
This federal Project Grant award for $853,135 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant will fund research at Dignity Health's St. Joseph's Hospital and Medical Center in Phoenix, AZ to study the role of the complement C3A receptor in exacerbating brain injury and functional impairment following ischemic stroke. The research aims to...
This federal Project Grant award in the amount of $811,942 was provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the J. David Gladstone Institutes, a non-profit biomedical research organization, to investigate genetic factors conferring susceptibility to toxicant-induced Parkinson's disease. The research involves a sub-award to the Northern California Institute For Research And...
This federal Project Grant award of $325,142, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports the development of a clinical-grade spinal cord neuroprosthesis to alleviate locomotor deficits in people with Parkinson's disease. The award, which has a performance period from September 1, 2025 to August 31, 2028, is being provided to Onward Medical Inc., a for-profit organization located in Boston, MA. The goal of this...